[Form 4] Avidity Biosciences, Inc. Insider Trading Activity
Rhea-AI Filing Summary
Avidity Biosciences director Troy Edward Wilson reported multiple issuer dispositions of stock options and common shares tied to the company’s merger with Novartis. On February 27, 2026, stock options covering 10,034, 13,489, and 15,000 shares were disposed of for cash under the merger terms.
The footnotes state these options were cashed out at the merger consideration of $72.00 per share minus their exercise prices. In addition, 65,091 shares of common stock held directly and 13,711 shares held indirectly through a family trust were also disposed of pursuant to the merger agreement, converting the equity into cash consideration.
Positive
- None.
Negative
- None.
Insights
Director equity and options were cashed out as part of Avidity’s merger with Novartis.
The transactions show Troy Edward Wilson, a director of Avidity Biosciences, disposing of stock options and common shares because the company is being acquired by Novartis. The merger agreement sets cash consideration of $72.00 per share, which also drives the option payout formula.
Three option positions and two common stock holdings, including one via a family trust, were converted from equity into cash through issuer dispositions. This reflects standard change-of-control treatment for director equity rather than discretionary trading, and aligns director incentives with the agreed merger terms under the October 25, 2025 merger agreement.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 10,034 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 13,489 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 15,000 | $0.00 | -- |
| Disposition | Common Stock | 65,091 | $0.00 | -- |
| Disposition | Common Stock | 13,711 | $0.00 | -- |
Footnotes (1)
- The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
